Levocetirizine
Modify Date: 2024-01-04 06:47:26
Levocetirizine structure
|
Common Name | Levocetirizine | ||
|---|---|---|---|---|
| CAS Number | 130018-77-8 | Molecular Weight | 388.888 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 542.1±45.0 °C at 760 mmHg | |
| Molecular Formula | C21H25ClN2O3 | Melting Point | 205-208°C (dec.) | |
| MSDS | N/A | Flash Point | 281.6±28.7 °C | |
Use of LevocetirizineLevocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1]. |
| Name | Levocetirizine |
|---|---|
| Synonym | More Synonyms |
| Description | Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1]. |
|---|---|
| Related Catalog | |
| Target |
H1 receptor |
| In Vivo | Levocetirizine (0.4 mg/kg; oral administration; male Sprague-Dawley rats) treatment shows that the Cmax, AUC0-t , AUC0-∞ and t1/2 are 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively in Sprague-Dawley rats[1]. Animal Model: 30 male Sprague-Dawley rats (8 weeks old; 200-250 g)[1] Dosage: 0.4 mg/kg Administration: Oral administration (Pharmacokinetic Analysis) Result: The Cmax, AUC0-t , AUC0-∞ and t1/2 were 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 542.1±45.0 °C at 760 mmHg |
| Melting Point | 205-208°C (dec.) |
| Molecular Formula | C21H25ClN2O3 |
| Molecular Weight | 388.888 |
| Flash Point | 281.6±28.7 °C |
| Exact Mass | 388.155365 |
| PSA | 53.01000 |
| LogP | 2.16 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.589 |
| Storage condition | -20°C Freezer |
| Hazard Codes | Xn |
|---|---|
| HS Code | 2933599090 |
CAS#:1150310-68-1
CAS#:3926-62-3![(R)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-1-(S)-[N-(1-phenyIethyl)]acetamide Structure](https://image.chemsrc.com/caspic/066/1150310-67-0.png)
CAS#:1150310-67-0![1-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazine Structure](https://image.chemsrc.com/caspic/056/300543-56-0.png)
CAS#:300543-56-0
CAS#:163837-57-8
CAS#:28022-43-7| HS Code | 2933599090 |
|---|---|
| Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Levocetirizine [INN] |
| vardenafilH |
| Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- |
| Vivanza |
| MFCD04112703 |
| levocarnitine |
| (2-(4-((R)-(4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic Acid |
| (2-{4-[(R)-(4-Chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethoxy)acetic acid |
| (2-{4-[(R)-(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid |
| Vardenafil |
| (-)-Cetirizine |
| levocetirizinum |
| Acetic acid, 2-[2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- |
| (R)-Cetirizine |
| Levocetirizine |